Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS

Diabetes Care. 2016 Aug:39 Suppl 2:S210-8. doi: 10.2337/dcS15-3009.

Authors

Guntram Schernthaner¹, Avivit Cahn², Itamar Raz²

Affiliations

¹ Department of Medicine I, Rudolfstiftung Hospital, Vienna, Austria [email protected].
² Department of Internal Medicine, Hadassah University Hospital, Jerusalem, Israel.

PMID: 27440835
DOI: 10.2337/dcS15-3009

No abstract available

MeSH terms

Adamantane / analogs & derivatives
Adamantane / therapeutic use
Cardiovascular Diseases / epidemiology
Diabetes Mellitus, Type 2 / drug therapy*
Dipeptides / therapeutic use
Dipeptidyl-Peptidase IV Inhibitors / therapeutic use*
Heart Failure / epidemiology*
Humans
Hypoglycemic Agents / therapeutic use*
Piperidines / therapeutic use
Risk Factors
Sitagliptin Phosphate / therapeutic use
Uracil / analogs & derivatives
Uracil / therapeutic use

Substances

Dipeptides
Dipeptidyl-Peptidase IV Inhibitors
Hypoglycemic Agents
Piperidines
Uracil
saxagliptin
alogliptin
Adamantane
Sitagliptin Phosphate